However, inherent or acquired resistance of melanoma cells to BRAF inhibitors necessitates the discovery of new and improved anticancer agents, which work by suppressing other relevant molecular targets that play critical roles in the development and progression of melanoma. Here, BRAF is linked to melanoma.